A new mechanism for primary resistance to gefitinib in lung adenocarcinoma

The role of a novel G796A mutation in exon 20 of EGFR

Hidetaka Uramoto, Takeshi Uchiumi, Hiroto Izumi, Kimitoshi Kohno, Tsunehiro Oyama, Kenji Sugio, Kosei Yasumoto

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Subsets of non-small cell lung cancer (NSCLC) patients who carry activating somatic mutations of the epidermal growth factor receptor (EGFR) have demonstrated an increased probability of obtaining objective responses to the receptor tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib. However, a substantial proportion of the cases with somatic mutations, which suggest sensitivity to gefitinib, are primary resistant to it. A primary resistant case of lung adenocarcinoma that was found to carry both delE746-A750 and a G796A mutation in the EGFR is reported. In vitro, a stable clone of cells bearing the G796A mutation was approximately 50,000-fold less sensitive to gefitinib in comparison to cells carrying the delE746-A750 mutant EGFR. This study suggests that screening tumour samples for a range of EGFR mutations may improve our ability to identify the patients most likely to benefit from EFGR TKIs.

Original languageEnglish
Pages (from-to)2297-2303
Number of pages7
JournalAnticancer Research
Volume27
Issue number4 B
Publication statusPublished - Jul 1 2007
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Exons
Mutation
Receptor Protein-Tyrosine Kinases
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Clone Cells
gefitinib
Adenocarcinoma of lung
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

A new mechanism for primary resistance to gefitinib in lung adenocarcinoma : The role of a novel G796A mutation in exon 20 of EGFR. / Uramoto, Hidetaka; Uchiumi, Takeshi; Izumi, Hiroto; Kohno, Kimitoshi; Oyama, Tsunehiro; Sugio, Kenji; Yasumoto, Kosei.

In: Anticancer Research, Vol. 27, No. 4 B, 01.07.2007, p. 2297-2303.

Research output: Contribution to journalArticle

Uramoto, H, Uchiumi, T, Izumi, H, Kohno, K, Oyama, T, Sugio, K & Yasumoto, K 2007, 'A new mechanism for primary resistance to gefitinib in lung adenocarcinoma: The role of a novel G796A mutation in exon 20 of EGFR', Anticancer Research, vol. 27, no. 4 B, pp. 2297-2303.
Uramoto, Hidetaka ; Uchiumi, Takeshi ; Izumi, Hiroto ; Kohno, Kimitoshi ; Oyama, Tsunehiro ; Sugio, Kenji ; Yasumoto, Kosei. / A new mechanism for primary resistance to gefitinib in lung adenocarcinoma : The role of a novel G796A mutation in exon 20 of EGFR. In: Anticancer Research. 2007 ; Vol. 27, No. 4 B. pp. 2297-2303.
@article{5d9f32b853144806835770567be9405a,
title = "A new mechanism for primary resistance to gefitinib in lung adenocarcinoma: The role of a novel G796A mutation in exon 20 of EGFR",
abstract = "Subsets of non-small cell lung cancer (NSCLC) patients who carry activating somatic mutations of the epidermal growth factor receptor (EGFR) have demonstrated an increased probability of obtaining objective responses to the receptor tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib. However, a substantial proportion of the cases with somatic mutations, which suggest sensitivity to gefitinib, are primary resistant to it. A primary resistant case of lung adenocarcinoma that was found to carry both delE746-A750 and a G796A mutation in the EGFR is reported. In vitro, a stable clone of cells bearing the G796A mutation was approximately 50,000-fold less sensitive to gefitinib in comparison to cells carrying the delE746-A750 mutant EGFR. This study suggests that screening tumour samples for a range of EGFR mutations may improve our ability to identify the patients most likely to benefit from EFGR TKIs.",
author = "Hidetaka Uramoto and Takeshi Uchiumi and Hiroto Izumi and Kimitoshi Kohno and Tsunehiro Oyama and Kenji Sugio and Kosei Yasumoto",
year = "2007",
month = "7",
day = "1",
language = "English",
volume = "27",
pages = "2297--2303",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4 B",

}

TY - JOUR

T1 - A new mechanism for primary resistance to gefitinib in lung adenocarcinoma

T2 - The role of a novel G796A mutation in exon 20 of EGFR

AU - Uramoto, Hidetaka

AU - Uchiumi, Takeshi

AU - Izumi, Hiroto

AU - Kohno, Kimitoshi

AU - Oyama, Tsunehiro

AU - Sugio, Kenji

AU - Yasumoto, Kosei

PY - 2007/7/1

Y1 - 2007/7/1

N2 - Subsets of non-small cell lung cancer (NSCLC) patients who carry activating somatic mutations of the epidermal growth factor receptor (EGFR) have demonstrated an increased probability of obtaining objective responses to the receptor tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib. However, a substantial proportion of the cases with somatic mutations, which suggest sensitivity to gefitinib, are primary resistant to it. A primary resistant case of lung adenocarcinoma that was found to carry both delE746-A750 and a G796A mutation in the EGFR is reported. In vitro, a stable clone of cells bearing the G796A mutation was approximately 50,000-fold less sensitive to gefitinib in comparison to cells carrying the delE746-A750 mutant EGFR. This study suggests that screening tumour samples for a range of EGFR mutations may improve our ability to identify the patients most likely to benefit from EFGR TKIs.

AB - Subsets of non-small cell lung cancer (NSCLC) patients who carry activating somatic mutations of the epidermal growth factor receptor (EGFR) have demonstrated an increased probability of obtaining objective responses to the receptor tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib. However, a substantial proportion of the cases with somatic mutations, which suggest sensitivity to gefitinib, are primary resistant to it. A primary resistant case of lung adenocarcinoma that was found to carry both delE746-A750 and a G796A mutation in the EGFR is reported. In vitro, a stable clone of cells bearing the G796A mutation was approximately 50,000-fold less sensitive to gefitinib in comparison to cells carrying the delE746-A750 mutant EGFR. This study suggests that screening tumour samples for a range of EGFR mutations may improve our ability to identify the patients most likely to benefit from EFGR TKIs.

UR - http://www.scopus.com/inward/record.url?scp=34547749507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547749507&partnerID=8YFLogxK

M3 - Article

VL - 27

SP - 2297

EP - 2303

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4 B

ER -